Genomic News and Research

RSS

Genetic mutations could help explain cause of cancer in pediatric patients

Combined whole exome tumor and blood sequencing in pediatric cancer patients revealed mutations that could help explain the cause of cancer or have the potential to impact clinical cancer care in 40 percent of patients in a study led by researchers from Baylor College of Medicine and Texas Children's Cancer Center.

29 Jan 2016

VARI-SU2C Epigenetics Dream Team supports new clinical trial that targets metastatic colorectal cancer

The first clinical trial to move forward as part of the Van Andel Research Institute-Stand Up To Cancer (VARI-SU2C) Epigenetics Dream Team will target metastatic colorectal cancer, the second leading cause of cancer deaths among men and women combined in the U.S.

29 Jan 2016

Study provides detailed new information about diffuse glioma

An international collaborative study has revealed detailed new information about diffuse glioma, the most common type of tumor found in some 80 percent of adult brain cancer patients, raising hopes that better understanding of these disease groups may aid improved clinical outcomes.

29 Jan 2016

Scientists pin down molecular process linked to schizophrenia origin

For the first time, researchers have managed to home in on a molecular process in the brain that contributes to the development of schizophrenia.

28 Jan 2016

CosmosID announces $6M in Series B funding round

CosmosID, the leading genomic big data company focused on microbiome research, outbreak investigations, and infectious disease diagnostics, using next-generation DNA sequencing, announced $6M in Series B funding.

28 Jan 2016

Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Leaders of several cancer centers designated by the National Cancer Institute have united to support human papillomavirus vaccination. Among them is Cheryl Willman, MD, Director and CEO of the University of New Mexico Comprehensive Cancer Center.

28 Jan 2016

DNA imprinting defect may affect children diagnosed with osteosarcoma

Children diagnosed with osteosarcoma may be impacted by a DNA imprinting defect also found in parents, according to new research from the Masonic Cancer Center, University of Minnesota. DNA imprinting is a phenomenon in which just one of the two inherited genes is active while the other is present but inactive.

27 Jan 2016

Patients who receive information about coronary artery disease risk make improvements to health behaviors

A new study led by researchers at Brigham and Women's Hospital has found that providing unanticipated information about risk of coronary artery disease during a genetic risk assessment for Alzheimer's disease helped some participants cope with their results, and also motivated participants to make changes to their health behaviors.

27 Jan 2016

Using acidity to detect cancer

Normally, tissues demonstrate a slightly acidic intracellular pH (pHi) and slightly alkaline extracellular pH (pHe). However, proliferating tissues demonstrate transient pH Gradient Reversal i.e. alkalinization of pHi and acidification of pHe.

26 Jan 2016

Sensitive computational method could help reveal effect of the immune system on cancer

A study by researchers at Norris Cotton Cancer Center has shown that a very sensitive computational method can be used to reveal the human immune system's effect on cancer. The Dartmouth study was the first to perform an in-depth computational examination of how immune activity translates to prognosis in breast cancer.

22 Jan 2016

MDxHealth recognized with 2015 Global Frost & Sullivan Award for Technology Innovation

Based on its recent analysis of the prostate cancer diagnostics market, Frost & Sullivan recognizes MDxHealth with the 2015 Global Frost & Sullivan Award for Technology Innovation. To advance molecular diagnostic tests for urological cancers, MDxHealth supplemented its prostate cancer test, ConfirmMDx, with a urine-based "liquid-biopsy" test called SelectMDx.

21 Jan 2016

Paradigm, UnitedHealthcare sign contractual agreement for coverage of PCDx

Paradigm, a molecular information & Next Generation Sequencing corporation specializing in providing testing for cancer patients today announced that it has entered into a contractual agreement with UnitedHealthcare for coverage of PCDx.

21 Jan 2016

Combination of PARP inhibitors and c-MET may benefit breast cancer patients

Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced by combining them with inhibitors targeting an oncogene known as c-MET which is overexpressed in many cancers.

19 Jan 2016

Researchers reveal totally new biological mechanism that underlies cancer

In a landmark study, researchers from the Broad Institute and Massachusetts General Hospital reveal a completely new biological mechanism that underlies cancer. By studying brain tumors that carry mutations in the isocitrate dehydrogenase (IDH) genes, the team uncovered some unusual changes in the instructions for how the genome folds up on itself.

13 Jan 2016

UHN's multi-disciplinary team successfully completes Canada's first transplant of the upper limb

In a Canadian first, a multi-disciplinary team, led by Dr. Steven McCabe, has successfully completed the country's first transplant of the upper limb.

13 Jan 2016

Genomics portfolio expanded by Illumina

Illumina, Inc., the global leader in sequencing and array-based technologies, today announced the newest addition to its industry-leading next-generation sequencing (NGS) portfolio with the launch of the MiniSeq Sequencing System.

From Illumina, Inc. 12 Jan 2016

LabCorp to offer Interpace's new ThyraMir microRNA classifier test

Interpace Diagnostics announced today that Laboratory Corporation of America Holdings, the world's leading health care diagnostics company, will begin offering Interpace's new ThyraMir microRNA classifier test.

12 Jan 2016

Syapse closes $25 million Series C funding round

Syapse, the leader in precision medicine software, has completed the first close of a $25 million Series C funding round. The financing round is being led by Ascension Ventures, a subsidiary of Ascension, the nation's largest non-profit and Catholic health system.

12 Jan 2016

Three new genetic associations identified for primary open angle glaucoma

Researchers from Massachusetts Eye and Ear/Harvard Medical School and Case Western Reserve University School of Medicine have led an international effort to identify three genetic associations that influence susceptibility to primary open angle glaucoma -- the most common form of adult onset glaucoma and the leading cause of irreversible blindness in the world.

12 Jan 2016

MD Anderson-led study explores role of HIF-1 in triple-negative breast cancer

A multi-institutional international study led by scientists at The University of Texas MD Anderson Cancer Center has revealed new information about how molecules called long non-coding RNAs (lncRNA) interact with HIF-1, a signaling pathway that is overexpressed in many cancers. HIF-1 has been shown to regulate breast cancer progression.

12 Jan 2016